FDA Review Clock Explained: Timelines, Pauses, and PDUFA Goals
The FDA review clock is the timeline framework governing how long FDA has to review marketing applications (NDAs, BLAs, efficacy supplements). Under PDUFA VII, the standard review goal is 10 months from the date of submission, and the priority review goal is 6 months. The clock "starts" on the day FDA receives the application, the "filing date" is set approximately 60 days later, and the clock can be effectively extended by 3 months when the sponsor submits a major amendment. Understanding these mechanics is essential for launch planning and regulatory strategy.
Key Takeaways
Key Takeaways
- The PDUFA goal date is calculated from the submission date (Day 0), not the filing date set retroactively at Day 60
- Standard review is 10 months from submission; priority review is 6 months — these are performance goals, not legal mandates
- A major amendment extends the PDUFA date by 3 months from the date FDA receives the amendment
- FDA meeting the PDUFA date means taking any action (approval or CRL), not necessarily a favorable outcome
- ANDA review timelines are governed by GDUFA, not PDUFA, with different performance goals and amendment rules
- Every sponsor preparing a New Drug Application or Biologics License Application needs to understand the FDA review clock. This framework, established through the Prescription Drug User Fee Act (PDUFA) and its successive reauthorizations, defines the timelines FDA commits to for reviewing marketing applications. These are performance goals, not legal mandates, but FDA meets them at rates exceeding 90% for most application types.
- The review clock is not a simple countdown. It has a defined start date, specific milestones, mechanisms for extension, and nuances that vary by application type. Misunderstanding these mechanics leads to incorrect launch planning, unrealistic investor communications, and poor resource allocation.
- In this guide, you will learn:
- How the PDUFA review clock starts and the relationship between submission date and filing date
- Standard review vs priority review timelines
- What pauses or extends the review clock
- How major amendments affect the PDUFA date
- Refuse to file implications for the clock
- Clock extension scenarios and how to plan for them
- ---
How the Review Clock Starts
Submission Date vs Filing Date
The review clock involves two critical dates that are frequently confused:
| Date | Definition | Regulatory Basis |
|---|---|---|
| Submission date (Day 0) | The date FDA receives the complete application | PDUFA commitment letter; the clock starts here for PDUFA goal calculation |
| Filing date | The date FDA formally accepts the application for review (after completing filing review) | 21 CFR 314.101(a) |
| PDUFA goal date | The date by which FDA aims to complete its review and take an action | Calculated from the submission date |
The Filing Review Period
After FDA receives an application, it conducts a filing review to determine whether the application is sufficiently complete to permit a substantive review. This filing review takes approximately 60 days for NDAs and BLAs.
| Filing Review Timeline | NDA/BLA |
|---|---|
| Filing review period | ~60 days from receipt |
| Filing decision communicated | By Day 74 (the "Day 74 letter") |
| Filing date (if accepted) | Set retroactively to Day 60 |
| Refuse to file decision | Communicated by Day 74 |
The PDUFA goal date is calculated from the submission date (Day 0), not from the filing date. This means the filing review period counts toward the total PDUFA review time. A 10-month standard review means 10 months from the day FDA received the application, not 10 months from filing acceptance.
Day 74 Letter
The Day 74 letter is FDA's communication to the sponsor regarding the filing decision. It is sent approximately 74 days after the submission date and communicates one of three outcomes:
| Outcome | Meaning | PDUFA Impact |
|---|---|---|
| Application filed | FDA accepts the application for review | PDUFA clock continues; goal date stands |
| Refuse to file (RTF) | FDA determines the application is insufficiently complete | PDUFA clock stops; goal date is voided |
| Filing with issues noted | FDA files the application but identifies deficiencies that may need to be addressed | PDUFA clock continues; deficiencies flagged for review |
Standard Review vs Priority Review
Timeline Comparison
| Attribute | Standard Review | Priority Review |
|---|---|---|
| PDUFA goal | 10 months from submission date | 6 months from submission date |
| Eligibility | Default for all applications | Drugs that offer significant improvement over existing treatments |
| Regulatory basis | PDUFA VII commitment letter | PDUFA VII commitment letter; FDA Guidance "Priority Review Designations" |
| Request timing | Not applicable (default) | At time of NDA/BLA submission or within 60 days of submission |
| FDA decision on designation | Not applicable | Within 60 days of submission |
| Filing review period | ~60 days | ~60 days |
| Mid-cycle meeting | Month 5-6 from filing | Month 2-3 from filing |
| Late-cycle meeting | Month 6-7 from filing | Month 3-4 from filing |
Priority Review Designation Criteria
Under PDUFA performance commitments, priority review is granted to applications for drugs that, if approved, would represent a significant improvement in the safety or effectiveness of the treatment, diagnosis, or prevention of a serious condition compared to available therapies.
Factors FDA considers:
- Evidence of increased efficacy
- Avoidance of serious side effects of available therapy
- Improved patient compliance
- New therapeutic for a condition with no approved treatment
- Evidence of safety and effectiveness in a new subpopulation
Priority review designation affects the review timeline but does not change the standard of evidence required for approval. A priority review drug must meet the same safety and efficacy standards as a standard review drug. The designation simply compresses FDA's review period from 10 months to 6 months.
What Affects the Review Clock
Events That Extend the PDUFA Date
The primary mechanism for extending the PDUFA goal date is the submission of a major amendment by the sponsor:
| Event | Impact on PDUFA Date | Mechanism |
|---|---|---|
| Major amendment | Extends by 3 months from the date of the amendment | PDUFA commitment letter provision |
| Multiple major amendments | Each can independently extend; the PDUFA date is set based on the most recent major amendment | Cumulative extensions possible |
Major Amendment Definition
Under PDUFA commitments, a major amendment is a submission by the sponsor that:
- Contains significant new data or analyses that require substantial additional review time
- Includes a new clinical study report or reanalysis of pivotal data
- Introduces major CMC changes (new manufacturing site, process change, new formulation)
- Is submitted within the last 3 months of the review cycle and contains more than minor clarifications
When FDA determines that a sponsor submission constitutes a major amendment, the PDUFA goal date is reset to 3 months from the date FDA received the amendment.
Major Amendment Extension Calculation
| Scenario | Original PDUFA Date | Amendment Received | New PDUFA Date |
|---|---|---|---|
| Standard review, amendment Month 5 | Month 10 | Month 5 | Month 10 (no change; 3 months from amendment = Month 8, which is before the original PDUFA date) |
| Standard review, amendment Month 8 | Month 10 | Month 8 | Month 11 (3 months from Month 8) |
| Standard review, amendment Month 9 | Month 10 | Month 9 | Month 12 (3 months from Month 9) |
| Priority review, amendment Month 4 | Month 6 | Month 4 | Month 7 (3 months from Month 4) |
The 3-month extension from a major amendment only extends the PDUFA date if the extension date falls after the current PDUFA date. If you submit a major amendment early in the review (e.g., Month 3 of a 10-month review), the 3-month extension (Month 6) is still before the original PDUFA date (Month 10), so there is no effective extension.
Events That Do NOT Extend the PDUFA Date
| Event | Why No Extension |
|---|---|
| Minor amendment | Does not require significant additional review time |
| FDA information request | The IR itself does not change the clock; only the sponsor's response (if classified as major) affects it |
| Mid-cycle or late-cycle meeting | Communication milestones, not regulatory actions |
| Advisory committee meeting | Advisory meetings are scheduled within the review period and do not extend it |
| Pre-approval inspection | Inspections are planned within the review timeline; only PAI failures that require sponsor remediation and resubmission may indirectly lead to extensions |
| FDA internal delays | FDA workload or staffing issues do not change the PDUFA date (though FDA may miss the goal date) |
Refuse to File and the Review Clock
Clock Impact of RTF
When FDA issues a refuse to file (RTF) decision:
| Timeline Element | Impact |
|---|---|
| PDUFA date | Voided; no longer applicable |
| Filing date | Never established (application was not filed) |
| Review clock | Effectively never started for substantive review purposes |
| Resubmission | Treated as a new original application with a new PDUFA date |
RTF vs RTR Clock Implications
| Decision | Clock Status | Next Steps |
|---|---|---|
| Refuse to receive (RTR) | Clock never starts; application returned at intake | Resubmit as new application |
| Refuse to file (RTF) | Clock started at submission but voided at Day 74 | Resubmit as new application |
| Filed with issues | Clock continues; PDUFA date stands | Address issues during review |
Clock Extension Scenarios
Scenario 1: Sponsor-Initiated Major Amendment
The most common extension scenario. The sponsor identifies a need to submit additional data (e.g., updated clinical results, new stability data, revised manufacturing process) and submits a major amendment during the review period.
Example: A sponsor submits an NDA on January 1 (Month 0). The 10-month PDUFA date is November 1. In Month 8 (September 1), the sponsor submits a major amendment with a new analysis of the primary endpoint. The PDUFA date extends to December 1 (3 months from September 1).
Scenario 2: FDA-Requested Information Leading to Major Amendment
FDA issues an information request during the review. The sponsor's response contains substantial new data that FDA classifies as a major amendment.
Example: FDA requests additional safety data in Month 6. The sponsor responds in Month 7 with a comprehensive safety analysis including data from an ongoing long-term extension study. FDA classifies this response as a major amendment. The PDUFA date extends from Month 10 to Month 10 (3 months from Month 7 = Month 10, same as original; no effective extension in this case).
Scenario 3: Late-Cycle Major Amendment
The most impactful scenario for launch planning. A major amendment submitted in the last 2-3 months of the review pushes the PDUFA date well beyond the original goal.
Example: A priority review drug has a PDUFA date at Month 6. In Month 5, FDA identifies a manufacturing issue during PAI. The sponsor submits remediation data in Month 5 that FDA classifies as a major amendment. The PDUFA date extends to Month 8.
Scenario 4: Multiple Major Amendments
If a sponsor submits more than one major amendment, each independently can extend the PDUFA date. The PDUFA date is set based on the most recent major amendment.
Example: A sponsor submits a major amendment in Month 6 (new PDUFA date: Month 9). In Month 8, the sponsor submits another major amendment with additional CMC data (new PDUFA date: Month 11).
PDUFA Goal Date Performance
FDA's Track Record
Under successive PDUFA reauthorizations, FDA has maintained high on-time action rates:
| PDUFA Cycle | Standard Review On-Time (%) | Priority Review On-Time (%) |
|---|---|---|
| PDUFA V (FY2013-2017) | >90% | >90% |
| PDUFA VI (FY2018-2022) | >90% | >90% |
| PDUFA VII (FY2023-2027) | In progress | In progress |
"On-time" means FDA took an action (approval, CRL, or other) on or before the PDUFA goal date. It does not mean the application was approved.
FDA meeting the PDUFA date means taking any action, not necessarily a favorable action. A CRL issued on the PDUFA date counts as an on-time action in FDA's performance metrics. Do not conflate PDUFA date adherence with approval likelihood.
Practical Implications for Launch Planning
Timeline Planning Framework
| Planning Milestone | When to Plan For |
|---|---|
| Best case (no amendments) | PDUFA goal date as originally calculated |
| Base case (one minor amendment) | PDUFA goal date (no change) |
| Conservative case (one major amendment) | PDUFA goal date + 3 months |
| Worst case (multiple major amendments or CRL) | PDUFA goal date + 6-12 months |
What to Track
| Element | Monitoring Approach |
|---|---|
| Filing status | Confirm filing via Day 74 letter |
| Amendment classification | Track each submission to FDA and its classification |
| Mid-cycle communication | Note any signals that may indicate upcoming information requests |
| PAI scheduling and results | Monitor inspection status; unresolved PAI findings can lead to CRL |
| Advisory committee | Track whether AdComm is planned; prepare contingency for negative vote |
| PDUFA date recalculation | Update internal timeline after each major amendment |
Key Regulatory References
| Document | Relevance |
|---|---|
| PDUFA VII Commitment Letter (2022) | Review timeline goals, major amendment definitions, performance metrics |
| 21 CFR 314.101 | Filing and completeness requirements for NDAs |
| 21 CFR 601.2 | Filing requirements for BLAs |
| 21 CFR 314.105 | NDA approval provisions |
| FDA Guidance: "PDUFA Reauthorization Performance Goals and Procedures" (PDUFA VII) | Detailed performance commitments including review timelines |
| FDA Guidance: "Priority Review Designations" | Eligibility criteria and process for priority review designation |
| 21 CFR 314.110 | Complete response letter provisions |
What is the difference between the submission date and the filing date?
The submission date is Day 0, the day FDA receives the application. The filing date is set retroactively to approximately Day 60 after FDA completes its filing review and accepts the application. The PDUFA goal date is calculated from the submission date, not the filing date.
Can FDA extend the review clock on its own?
FDA does not unilaterally extend the PDUFA date. Only a major amendment from the sponsor triggers a 3-month extension. If FDA needs more time but no major amendment is filed, FDA may miss the PDUFA date (rare) or issue a CRL citing outstanding issues.
What happens if FDA misses the PDUFA date?
FDA continues its review and takes action when the review is complete. There is no statutory penalty for FDA missing a PDUFA goal date, though it is tracked in PDUFA performance reports. FDA misses PDUFA dates infrequently.
Does a priority review voucher (PRV) change the review clock?
A PRV entitles the holder to priority review (6-month timeline) for a future NDA or BLA. It changes the review timeline from standard (10 months) to priority (6 months) but does not otherwise alter the review clock mechanics.
Are ANDA review timelines governed by the same clock?
No. ANDA review timelines are governed by the Generic Drug User Fee Act (GDUFA), which has its own performance goals. GDUFA goal dates and amendment classification rules differ from PDUFA.
Does the review clock apply to supplements?
Yes. Efficacy supplements to approved NDAs and BLAs are subject to PDUFA review timelines (standard and priority). Manufacturing supplements follow different timelines depending on the supplement type (Prior Approval, CBE-30, CBE-0, Annual Report).